دورية أكاديمية
أعرض في EDS

Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.

التفاصيل البيبلوغرافية
العنوان: Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS.
المؤلفون: Yang Y; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA.; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA., Brown MC; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Zhang G; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Stevenson K; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Mohme M; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kornahrens R; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Bigner DD; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Ashley DM; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., López GY; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA., Gromeier M; Department of Neurosurgery, Duke University Medical School, Durham, NC, USA.
المصدر: Neuro-oncology [Neuro Oncol] 2023 Sep 05; Vol. 25 (9), pp. 1631-1643.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : Oxford : Oxford University Press
Original Publication: 1999-<2002> : Charlottesville, VA : Carden Jennings Pub.,
مواضيع طبية MeSH: Oncolytic Virotherapy* , Glioma*/therapy , Brain Neoplasms*/metabolism , Poliomyelitis*/therapy, Animals ; Mice ; Microglia/metabolism ; B7-H1 Antigen ; Inflammation
مستخلص: Background: Malignant gliomas commandeer dense inflammatory infiltrates with glioma-associated macrophages and microglia (GAMM) promoting immune suppression, evasion, and tumor progression. Like all cells in the mononuclear phagocytic system, GAMM constitutively express the poliovirus receptor, CD155. Besides myeloid cells, CD155 is widely upregulated in the neoplastic compartment of malignant gliomas. Intratumor treatment with the highly attenuated rhino:poliovirus chimera, PVSRIPO, yielded long-term survival with durable radiographic responses in patients with recurrent glioblastoma (Desjardins et al. New England Journal of Medicine, 2018). This scenario raises questions about the contributions of myeloid versus neoplastic cells to polio virotherapy of malignant gliomas.
Methods: We investigated PVSRIPO immunotherapy in immunocompetent mouse brain tumor models with blinded, board-certified neuropathologist review, a range of neuropathological, immunohistochemical, and immunofluorescence analyses, and RNAseq of the tumor region.
Results: PVSRIPO treatment caused intense engagement of the GAMM infiltrate associated with substantial, but transient tumor regression. This was accompanied by marked microglia activation and proliferation in normal brain surrounding the tumor, in the ipsilateral hemisphere and extending into the contralateral hemisphere. There was no evidence for lytic infection of malignant cells. PVSRIPO-instigated microglia activation occurred against a backdrop of sustained innate antiviral inflammation, associated with induction of the Programmed Cell Death Ligand 1 (PD-L1) immune checkpoint on GAMM. Combining PVSRIPO with PD1/PD-L1 blockade led to durable remissions.
Conclusions: Our work implicates GAMM as active drivers of PVSRIPO-induced antitumor inflammation and reveals profound and widespread neuroinflammatory activation of the brain-resident myeloid compartment by PVSRIPO.
(© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
References: Glia. 2022 May;70(5):875-891. (PMID: 35025109)
Science. 1991 May 10;252(5007):854-6. (PMID: 1851332)
J Neurosurg. 1979 Mar;50(3):305-11. (PMID: 422981)
Cancer Res. 2007 Oct 1;67(19):9398-406. (PMID: 17909049)
J Virol. 2012 Mar;86(5):2750-9. (PMID: 22171271)
Science. 2010 Nov 5;330(6005):841-5. (PMID: 20966214)
J Histochem Cytochem. 2007 Jul;55(7):687-700. (PMID: 17341475)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Neuro Oncol. 2004 Jul;6(3):208-17. (PMID: 15279713)
J Virol. 2005 Jan;79(1):401-9. (PMID: 15596833)
Cell. 1989 Mar 10;56(5):855-65. (PMID: 2538245)
Science. 1956 Jun 29;123(3209):1151-7. (PMID: 13337331)
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):951-5. (PMID: 1846972)
Annu Rev Med. 2018 Jan 29;69:289-299. (PMID: 29414253)
Mol Chem Neuropathol. 1992 Oct;17(2):147-67. (PMID: 1418222)
Sci Immunol. 2020 Jun 5;5(48):. (PMID: 32503876)
J Virol. 2014 Nov;88(22):13135-48. (PMID: 25187541)
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2370-5. (PMID: 8637880)
Cell Mol Immunol. 2021 Feb;18(2):250-258. (PMID: 33437050)
Science. 1955 Jul 15;122(3159):105-8. (PMID: 14385825)
J Virol. 2018 Sep 12;92(19):. (PMID: 29997212)
J Neurooncol. 2021 Jan;151(1):3-12. (PMID: 32542437)
J Virol. 2006 Apr;80(7):3147-56. (PMID: 16537583)
J Virol. 1999 Feb;73(2):958-64. (PMID: 9882296)
Nat Commun. 2021 Mar 25;12(1):1858. (PMID: 33767151)
Histol Histopathol. 2007 Dec;22(12):1309-26. (PMID: 17701911)
Cell Rep. 2018 Oct 2;25(1):118-129.e4. (PMID: 30282022)
Genome Biol. 2016 Oct 20;17(1):218. (PMID: 27765066)
Sci Transl Med. 2017 Sep 20;9(408):. (PMID: 28931654)
J Virol. 2017 Jun 26;91(14):. (PMID: 28356537)
Nat Neurosci. 2018 Apr;21(4):530-540. (PMID: 29472620)
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1738-46. (PMID: 26884166)
J Virol. 2006 Apr;80(7):3310-21. (PMID: 16537598)
Brain Res. 2014 Jul 29;1574:84-95. (PMID: 24928618)
Arch Pathol Lab Med. 2017 Dec;141(12):1697-1704. (PMID: 28829151)
J Transl Med. 2014 Apr 29;12:107. (PMID: 24779345)
J Clin Invest. 2012 Apr;122(4):1164-71. (PMID: 22466658)
Nat Commun. 2020 Jan 27;11(1):524. (PMID: 31988324)
N Engl J Med. 2018 Jul 12;379(2):150-161. (PMID: 29943666)
J Virol. 2014 Nov;88(22):13149-60. (PMID: 25187540)
Brain. 2017 Jun 1;140(6):1548-1560. (PMID: 28334886)
معلومات مُعتمدة: R00 CA263021 United States CA NCI NIH HHS; KL2 TR002554 United States TR NCATS NIH HHS; K99 CA263021 United States CA NCI NIH HHS; R01 NS108773 United States NS NINDS NIH HHS; F32 CA224593 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: glioma; immunotherapy; interferon; macrophages; microglia
المشرفين على المادة: 0 (B7-H1 Antigen)
تواريخ الأحداث: Date Created: 20230303 Date Completed: 20230906 Latest Revision: 20240303
رمز التحديث: 20240303
مُعرف محوري في PubMed: PMC10479910
DOI: 10.1093/neuonc/noad052
PMID: 36864784
قاعدة البيانات: MEDLINE
الوصف
تدمد:1523-5866
DOI:10.1093/neuonc/noad052